Loading patent…
OwnerKapil Maithal, Paromita Sengupta +1inventors
InventorsKapil Maithal, Paromita Sengupta, Rama Mukherjee
Estimating the term…
The invention relates to a fusion gene useful as a therapeutic and prophylactic vaccine against cancer. The fusion gene contains a DNA encoding ubiquitin gene fused to a second DNA encoding growth factor receptors or fragment thereof, over expressed in various types of cancer. In particular, the invention is illustrated by a recombinant fusion gene comprised of mutated ubiquitin gene and modified extra cellular domain of vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide receptor-1 (VPAC1). Immunization with the vaccine will break the self-tolerance for the tumor antigen through effective antigen processing and presentation, leading to retardation/regression of tumor growth.
A synthetic fusion gene comprising a sequence composed of an ubiquitin gene fused to a gene sequence encoding an extracellular domain of a growth factor receptor selected from vasoactive intestinal receptor type 1, vasoactive intestinal receptor type 2, somatostatin receptor type 1, somatostatin receptor type 2, somatostatin receptor type 3, somatostatin receptor type 4, somatostatin receptor type 5, neuromedin B receptor, gastrin-releasing peptide receptor, bombesin receptor type 3, bombesin receptor type 4, substance P receptor type 1, substance P receptor type 2, substance P receptor type 3, fibroblast growth factor receptor, or epithelial growth factor receptor, which are over expressed in cancer of various origins.
A synthetic fusion gene as claimed in claim L which is synthesized by recombinant DNA technology.
A DNA vaccine comprising a sequence composed of an ubiquitin gene fused to a gene sequence encoding an extracellular domain of a growth factor receptor selected from somatostatin receptor type 1, somatostatin receptor type 2, somatostatin receptor type 3, somatostatin receptor type 4, somatostatin receptor type 5, neuromedin B receptor, gastrin-releasing peptide receptor, bombesin receptor type 3, bombesin receptor type 4, substance P receptor type 1, substance P receptor type 2, substance P receptor type 3, fibroblast growth factor receptor, or epithelial growth factor receptor, which are over expressed in cancer of various origins.
Dependencies are inferred from the claim text.